A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera® A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safet ...